source
- EyePoint’s Phase 3 eye drug falls short of Eylea, stock tumbles 70%EyePoint reported that its experimental treatment for wet age-related macular degeneration did not meet the efficacy endpoints in a Phase 3 trial when compared with the current standard, Eylea. The…
- Biotech raises $820M to bring China-sourced immunology drug to market via reverse mergerA biotech company has secured $820 million in investor commitments this month to bring its immunology drug, developed in China, to public markets. The funding will be used to complete a reverse me…